Statistics for Viridian Therapeutics, (id:5271 VRDN)
Valuation metrics
Market cap
1.60B
Enterprise value
1.05B
Trailing P/E (ttm)
-3.80
Forward P/E
-4.82
PEG ratio
-4.82
Price/Sales (ttm)
5.28K
Price/Book (mrq)
3.07
Enterprise Value/Revenue
3.49K
Enterprise Value/EBITDA
-3.73
Overview
Shares outstanding
79.21M
Float
71.05M
Shares short
10.02M
% Held by insiders
0.00%
% Held by institutions
1.12%
Average volume (10 days)
1.42M
Average volume (90 days)
Price summary
52-Week low
11.40
52-Week high
27.20
52-Week change
19.26%
Beta
1.11
50-Day moving average
22.64
200-Day moving average
17.16
Dividends and splits
Forward annual dividend rate
Forward annual dividend yield
Trailing annual dividend rate
0.00%
Trailing annual dividend yield
0.00
5-Year annual dividend yield
Payout ratio
0.00
Dividend date
November 13th, 2020
Ex-dividend date
Last split factor
2:1
Last split date
November 13th, 2020
Financials
Fiscal yearFiscal year ends
December 31th, 2023
Most recent quarter (mrq)
September 30th, 2024
Profitability
Profit margin
0.00%
Operating margin
-97,069.76%
Operational effectiveness
Return on assets
-32.14%
Return on equity
-51.88%
Income statement
Revenue (ttm)
0.00
Revenue per share (ttm)
0.00
Quarterly revenue growth (yoy)
Gross profit (ttm)
0.00
EBITDA
-282,473,984.00
Net income to common (ttm)
-257,084,000.00
Diluted EPS (ttm)
-4.32
Quarterly earnings growth (yoy)
Balance sheet
Total cash (mrq)
753.24M
Total cash per share (mrq)
9.51
Total debt (mrq)
23.27M
Total Debt/Equity (mrq)
3.29
Current ratio (mrq)
1.86K%
Book value per share (mrq)
6.55
Cash flow
Cash flow statement
-196,987,008.00
Levered free cash flow (LFCF)
-104,008,496.00